珠海润都制药股份有限公司 2025年度业绩预告

Group 1 - The company expects a negative net profit for the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The preliminary estimate of the performance forecast has not been audited by registered accountants, but there are no significant disagreements between the company and the accounting firm regarding the forecast [1][2] Group 2 - The main reasons for the performance change include the ongoing implementation of national drug procurement policies, leading to a year-on-year decline in gross profit margins for major formulation products [2] - Intense competition in both domestic and international markets has resulted in further price declines for certain raw material intermediates, contributing to a decrease in the consolidated gross profit margin for these intermediates [2] - The company has disposed of some non-core product production lines, which has also impacted performance [2]